Pfizer will let go of 56 employees in San Diego effective June 6, according to a Worker Retraining Notification Act (WARN) notice. Affected roles include a vice president as well as several directors, managers and senior associates, the San Diego Union-Tribune reported. The newspaper noted that operations at the site will continue.
All entries for: Pfizer
April 11, 2025
Pfizer - San Diego
Layoffs
San Diego, CA
50,001+ employees
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
October 29, 2024
Pfizer
Negative Outlook
New York, NY
50,001+ employees
Albert Bourla, chairman and chief executive officer:
“Clearly, IRA overall is negative for innovation and does not promote a spirit that people could provide investments, but there are also some good things about it. So clearly, I wouldn’t like to see that the out-of-pocket that next year will be $167 per month for all your medicines for seniors.
“That, we want to be maintained. But this forced price setting is not a negotiation and also the penalty deal between — are things that needs to change.”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
April 22, 2024
Pfizer
Discontinued Research, Layoffs
New York, NY
50,001+ employees
“Pfizer is letting go an undisclosed number of employees and ending research operations at its site in Boulder, CO, the company confirmed to Endpoints News… At one point, it employed almost 300 people, according to Pfizer’s website… The site mainly focused on small molecules for oncology, according to Pfizer’s webpage for the location.”
1 Discontinued Research Program
Disease Area: Oncology
Drug Type: Small Molecule
March 4, 2024
Pfizer
Discontinued Research
New York, NY
50,001+ employees
“Pfizer briefed investors on the strategic priorities for its oncology business, which will be built on a portfolio focused more on antibody-drug conjugates and bispecific antibodies and far less on small molecules. Pfizer executives said the company’s change in business strategy is motivated in part by the disparity in how the Inflation Reduction Act’s drug price negotiation provisions treat biologics versus small molecule drugs… Company leaders said that the mix of small molecule drugs in its cancer portfolio will plummet from 94% last year to 35% in 2030.”
1 Discontinued Research Program
Disease Area: Oncology
Drug Type: Small Molecule
November 8, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
“The drug pricing provisions of the IRA, which was signed into law in August 2022, began to be implemented in 2023 and implementation efforts will continue over the next several years. In August 2023, the Biden Administration unveiled the first round of medicines subject to the “Medicare Drug Price Negotiation Program,” which requires manufacturers of select drugs to engage in a process with the Federal government to set new Medicare prices which would go into effect in 2026. Among the medicines included in the first round is Eliquis. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. In addition, changes to the Medicaid program or the federal 340B drug pricing program, including legal or legislative developments at the federal or state level with respect to the 340B program, could have a material impact on our business.”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
October 10, 2023
Pfizer
Layoffs
New York, NY
50,001+ employees
“Pfizer is conducting layoffs at its Boulder, CO research facility, months after announcing a retreat from a significant chunk of its early-stage research… The facility specialized in small molecule discovery, and housed nearly 300 employees, according to Pfizer’s website.”
Disease Area: Oncology
Drug Type: Small Molecule
August 9, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 10, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 1, 2022
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
General Impact: “Governmental laws and regulations affecting our operations, including, without limitation, the recently enacted Inflation Reduction Act of 2022, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule